HUYABIO International™ announced the regulatory approval for HBI-8000 monotherapy of relapsed or refractory adult T-cell leukemia/lymphoma (ATL) by the Japanese Pharmaceuticals and Medical Devices Agency. The drug was approved based on data from a Phase IIb study that involved 23 patients with aggressive ATL in Japan.
[HUYABIO InternationalTM (PR Newswire, Inc.)]
7992332
nan
items
1
apa
0
default
asc
1
163775
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
